酒精性肝病的肠道作用机制新进展

摘要/Abstract

摘要： 酒精性肝病仍缺乏有效治疗药物。酒精代谢可直接引起肝细胞凋亡和肝组织炎性损伤。酒精引起肠道屏障受损,肠道菌群失调可改变肠道和肝脏的免疫微环境,肠道微生物及其衍生物移位可促进酒精性肝病进展。深入了解酒精性肝病不同阶段的肠道免疫特点、微生物组变化、屏障功能障碍,以及对肝损伤的影响和作用机制,对于酒精性肝病的诊疗研发具有重要价值。

关键词: 酒精性肝病, 肠道菌群失调, 肠道免疫, 肠-肝轴

王泳而, 汪艳. 酒精性肝病的肠道作用机制新进展[J]. 肝脏, 2023, 28(12): 1399-1402.

[1] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol, 2023. 79(2): 516-537.
[2] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016. 65(5):830-839.
[3] Lang S, Schnabl B, Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe, 2020, 28(2): 233-244.
[4] Lowe PP, Gyongyosi B, Satishchandran A, et al. Reduced gut microbiome protects from alcohol-induced neuroinflammation and alters intestinal and brain inflammasome expression. J Neuroinflammation, 2018. 15(1): 298.
[5] Chen P, Stärkel P, Turner JR, et al.Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology, 2015. 61(3): 883-894.
[6] Inamine T, Yang AM, Wang L, et al. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohol Clin Exp Res, 2016. 40(12): 2604-2613.
[7] Gu M, Samuelson DR, Taylor CM, et al. Alcohol-associated intestinal dysbiosis alters mucosal-associated invariant T-cell phenotype and function. Alcohol Clin Exp Res, 2021. 45(5): 934-947.
[8] Riva A, Patel V, Kurioka A, et al. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut, 2018. 67(5): 918-930.
[9] Hendrikx T, Duan Y, Wang Y, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019. 68(8): 1504-1515.
[10] Yue R, Wei X, Zhao J, et al. Essential Role of IFN-gamma in Regulating Gut Antimicrobial Peptides and Microbiota to Protect Against Alcohol-Induced Bacterial Translocation and Hepatic Inflammation in Mice. Front Physiol, 2020,11: 629141.
[11] Hao L, Zhong W, Woo J, et al. Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining Akkermansia muciniphila in alcoholic steatohepatitis. Hepatology, 2023. 78(3):096-910.
[12] Grander C, Adolph TE, Wieser V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut, 2018. 67(5): 891-901.
[13] Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res, 2015. 39(5): 763-775.
[14] An L, Wirth U, Koch D, et al. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. J Gastrointest Surg, 2022. 26(3): 671-683.
[15] Jia L, Chang X, Qian S, et al. Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. Mol Metab, 2018. 14: 121-129.
[16] Saikia P, Roychowdhury S, Bellos D, et al. Hyaluronic acid 35 normalizes TLR4 signaling in Kupffer cells from ethanol-fed rats via regulation of microRNA291b and its target Tollip. Sci Rep, 2017. 7(1): 15671.
[17] Zhou H, Yu M, Roychowdhury S, et al. Myeloid-MyD88 Contributes to Ethanol-Induced Liver Injury in Mice Linking Hepatocellular Death to Inflammation. Alcohol Clin Exp Res, 2017. 41(4): 719-726.
[18] Duan Y, Chu H, Brandl K, et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun, 2021. 12(1): 7172.
[19] Gao B, Emami A, Nath S, et al. Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. Mol Nutr Food Res, 2021. 65(5): e2000023.
[20] Zhou R, Llorente C, Cao J, et al. Deficiency of Intestinal alpha1-2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. Alcohol Clin Exp Res, 2020. 44(9):1842-1851.
[21] Zhou R, Llorente C, Cao J, et al. Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. Cell Mol Gastroenterol Hepatol, 2021. 12(1): 293-320.
[22] Singhal R, Donde H, Ghare S, et al. Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogenic feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice. Gut Microbes, 2021. 13(1): 1946367.
[23] Donde H, Ghare S, Joshi-Barve S, et al. Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury. Cell Mol Gastroenterol Hepatol, 2020. 9(4): 569-585.
[24] Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology, 2015. 148(1): 203-214 e16.
[25] Warner J, Hardesty J, Song Y, et al. Fat-1 Transgenic Mice With Augmented n3-Polyunsaturated Fatty Acids Are Protected From Liver Injury Caused by Acute-On-Chronic Ethanol Administration. Front Pharmacol, 2021. 12: 711590.
[26] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018. 67(6):2150-2166.
[27] Spatz M, Ciocan D, Merlen G, et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. JHEP Rep, 2021. 3(2): 100230.
[28] Matye DJ, Li Y, Chen C, et al. Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice. Alcohol Clin Exp Res, 2021. 45(6): 1188-1199.
[29] Zhang M, Kong B, Huang M, et al. FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice. Dig Liver Dis, 2018. 50(10): 1068-1075.
[30] Huang M, Kong B, Zhang M, et al. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest, 2020. 100(9): 1158-1168.
[31] Wu WB, Chen YY, Zhu B, et al. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice. Biochimie, 2015. 115: 86-92.
[32] Gao B, Duan Y, Lang S, et al. Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis. Hepatol Commun, 2020. 4(8): 1168-1182.
[33] Gu Z, Li F, Liu Y, et al. Exosome-Like Nanoparticles From Lactobacillus rhamnosusGG Protect Against Alcohol-Associated Liver Disease Through Intestinal Aryl Hydrocarbon Receptor in Mice. Hepatol Commun, 2021. 5(5): 846-864.
[34] Qian M, Liu J, Zhao D, et al. Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. Cell Mol Gastroenterol Hepatol, 2022. 13(1): 233-256.

酒精性肝病的肠道作用机制新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高沿航. 酒精性肝病[J]. 肝脏, 2024, 29(1): 21-26.
[2]	陈璐, 杨妙芳, 汪芳裕. “口-肠-肝轴”在非酒精性脂肪性肝病中的作用[J]. 肝脏, 2024, 29(1): 110-113.
[3]	马驰, 杨涓, 郑盛. 肠道菌群与肝脏疾病研究进展[J]. 肝脏, 2024, 29(1): 113-116.
[4]	郭蕊, 崔莹, 王诗美, 樊微微, 胡晓丽. 慢性肝病患者相关骨病的研究进展[J]. 肝脏, 2022, 27(6): 711-715.
[5]	苑广菲, 孙悦, 孟方园, 高沿航. 酒精性肝病未被满足的临床需求与挑战[J]. 肝脏, 2022, 27(5): 508-510.
[6]	柳涛, 刘雅丽, 肖鹏, 高沿航. 遗传变异对酒精性肝病的影响[J]. 肝脏, 2022, 27(4): 389-390.
[7]	杜迪, 张宇迪, 刘彦. 重症酒精性肝病合并巨细胞病毒感染1例[J]. 肝脏, 2022, 27(2): 250-251.
[8]	孟方园, 孙悦, 苑广菲, 高沿航. 噬菌体在酒精性肝病治疗中的应用进展[J]. 肝脏, 2021, 26(9): 956-957.
[9]	苑广菲, 孟方园, 阿迪拉·亚克普, 高沿航. 酒精性肝病临床试验的难点与进展[J]. 肝脏, 2021, 26(7): 711-712.
[10]	周梅月, 全卉, 陈贺宁, 江宇泳. Gao-Binge酒精性肝病模型小鼠的损伤特点[J]. 肝脏, 2021, 26(12): 1407-1410.
[11]	张飞宇, 赵金明, 阿迪拉·亚克普, 高沿航. 全球酒精性肝病的疾病负担及干预策略[J]. 肝脏, 2021, 26(11): 1210-1213.
[12]	张行行, 李慧瑛, 陈华. 以弥漫性肝肿大为特征的早期酒精性肝硬化1例[J]. 肝脏, 2021, 26(11): 1299-1300.
[13]	张黎雯, 任明星, 薛国昌, 沈琳娜, 夏雪霞, 宋月娟, 夏欢. 肠道菌群失调对肥胖儿童非酒精性脂肪肝发生的影响[J]. 肝脏, 2020, 25(7): 755-758.
[14]	周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究[J]. 肝脏, 2020, 25(5): 521-524.
[15]	张娟, 徐少勇, 赵晓宏, 黄雪, 张根生, 周庆元. 非酒精性脂肪性肝病患者肠道微生态差异性及其与糖脂代谢相关指标的关系[J]. 肝脏, 2020, 25(4): 432-435.